L Gellman1, B Salky, M Edye. 1. Division of Laparoscopic Surgery, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Abstract
BACKGROUND: The role and feasibility of laparoscopic assisted colectomy (LAC) in both benign and malignant disease of the colon are not clear. We have reviewed our series in an effort to further delineate whether or not LAC is appropriate in the treatment of colonic disease. METHODS: This is a retrospective view of a personal series focusing on feasibility, cure of malignant disease, and length of stay (LOS). RESULTS: One hundred and two LACs were completed out of 104 attempts (98%). There were no wound or trocar implants in the Dukes A, B and C patients. Lymph node retrieval was similar in the laparoscopic and open historical controls. The LOS was 5.9 days in the LAC group as compared with 11 days in the open group. There was a 4.8% major morbidity rate and a 1% mortality rate in this series. CONCLUSIONS: LAC is technically feasible in a high percentage of patients. While a definite statement regarding its use in malignant disease can not be ascertained from this review, the preliminary results are encouraging. A randomized trial comparing open and LAC is warranted.
BACKGROUND: The role and feasibility of laparoscopic assisted colectomy (LAC) in both benign and malignant disease of the colon are not clear. We have reviewed our series in an effort to further delineate whether or not LAC is appropriate in the treatment of colonic disease. METHODS: This is a retrospective view of a personal series focusing on feasibility, cure of malignant disease, and length of stay (LOS). RESULTS: One hundred and two LACs were completed out of 104 attempts (98%). There were no wound or trocar implants in the Dukes A, B and C patients. Lymph node retrieval was similar in the laparoscopic and open historical controls. The LOS was 5.9 days in the LAC group as compared with 11 days in the open group. There was a 4.8% major morbidity rate and a 1% mortality rate in this series. CONCLUSIONS: LAC is technically feasible in a high percentage of patients. While a definite statement regarding its use in malignant disease can not be ascertained from this review, the preliminary results are encouraging. A randomized trial comparing open and LAC is warranted.
Authors: Sherief Shawki; Badma Bashankaev; Paula Denoya; Christina Seo; Eric G Weiss; Steven D Wexner Journal: Surg Endosc Date: 2009-03-06 Impact factor: 4.584
Authors: R Veldkamp; M Gholghesaei; H J Bonjer; D W Meijer; M Buunen; J Jeekel; B Anderberg; M A Cuesta; A Cuschierl; A Fingerhut; J W Fleshman; P J Guillou; E Haglind; J Himpens; C A Jacobi; J J Jakimowicz; F Koeckerling; A M Lacy; E Lezoche; J R Monson; M Morino; E Neugebauer; S D Wexner; R L Whelan Journal: Surg Endosc Date: 2004-06-23 Impact factor: 4.584